Keywords: peptech, join, aim, income, falls, australian, biopharmaceutical

Peptech to join AIM, as 2006 income falls 80.2%

Article | 04 December 2006

Australian biopharmaceutical company Peptech, a developer of antibody and peptide therapeutics for the treatment of inflammatory diseases and cancer, has ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Peptech

Go to company listing